Full Press Release Details
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC.
IDYA
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
Key Takeaway: IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
Price reaction · baseline $21.81 (2025-07-21 close) · hit after-hours · 4 other IDYA headline(s) in the window, move may be shared
day 0 close
+1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma